Lava Therapeutics B.V.
Kim Hofman has four years of experience in the biotechnology industry. In 2020, they began working as a Research Associate at Lava Therapeutics B.V., a biotechnology company that creates and develops next generation γδ T cell engaging bispecific antibodies for the treatment of cancer. Prior to this, they completed research internships at Sanquin in 2018 and AIMM Therapeutics in 2018, as well as a research internship at Universiteit van Amsterdam in 2017.
Kim Hofman completed a Bachelor of Science in Biomedical Sciences from the University of Amsterdam between 2014 and 2017. Kim then went on to complete a Master of Science in Biomedical Sciences (Oncology track) from the University of Amsterdam between 2017 and 2019.
This person is not in any offices
Lava Therapeutics B.V.
Lava Therapeutics is focused on applying its expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy.